Introduction Nedaplatin (cis-diammine-glycolate platinum) is a new anticancer agent developed in Japan. It is especially designed to reduce adverse side effects of CDDP such as renal toxicity and neurotoxicity. Aim We used nedaplatin as a superselective intra-arterial infusion chemotherapy for oral cancers and carried out a pharmacological study of the dose clearance of nedaplatin based on renal function as well as evaluating its efficacy, including hematological side effects. Patients and Methods Typical regimens of this chemotherapy consisted of 5-days straight of 24-h continuous intravenous infusion of 5-Fu with a single shot of nedaplatin via transfemoral artery on day 4. The dose of nedaplatin was calculated based on the 24-h creatine clearance. A total of 37 patients who had oral cancer and had received 68 courses (total) of chemotherapy were found to be eligible for this study. Results Total and free platinum concentrations in the plasma were measured at each of the time points, and the area under the curve (AUC, measured in units of lg h/ml) was calculated based on the platinum concentration with the following formula: CL (clearance of free platinum: l/h) = 0.042 9 CCr (ml/min) ? 5.84. The response rate was 70.1 % (in CR 51 %, in PR 19 %). Histological CR was seen in 28.6 % of surgical specimens. Moderate hematological side effects were seen. However, severe adverse events were not observed, including those associated with cannulation of the femoral artery. Conclusion The dose-clearance formula that was established by our study can most likely be utilized to accurately predict the optimal administered dose of nedaplatin for arterial infusion chemotherapy.
Introduction
Nedaplatin (cis-diammine-glycolate platinum, CDGP), that has been developed in Japan, produces anti-tumor effects after uptake into tumor cells by binding to DNA bases and inhibiting DNA replication like cisplatin (CDDP) and carboplatin (CBDCA) [1] . In this respect, this drug has a similar mechanism of action to that of its analogue, cisplatin [2] . CDGP has been reported to have high anti-tumor efficacy in clinical studies against head and neck cancer, esophageal cancer, lung cancer, urologic cancer, and gynecologic cancer [2] [3] [4] [5] [6] [7] [8] [9] .
Intra-arterial infusion chemotherapy has been used to treat head and neck cancers and has several theoretical advantages when compared with conventional venous infusion chemotherapy. In addition, favorable clinical outcomes have been reported in the literature [10] [11] [12] . The greatest advantage of arterial infusion chemotherapy is that higher drug concentrations are obtained at the tumor site while exhibiting only mild systemic toxicity due to relatively low levels of the agent in circulated blood. Both CDDP and CBDCA are clinically used on a regular basis for intra-arterial administration of chemotherapy to cancer patients and there have been several reports regarding platinum concentrations in blood and body tissues [11] [12] [13] [14] . However, despite these previous studies, the optimal dose for arterial infusion chemotherapy with CDGP is yet to be reported. To minimize side effects and to maximize the effect on cancer cells, it is important that the dose of the anticancer drug be individualized, even in cases where intra-arterial infusion chemotherapy is used. We have pharmacologically investigated the relationship between clearance of CDGP and renal function for this chemotherapy based on the creatinine clearance of oral cancer patients who have undergone superselective intra-arterial chemotherapy using nedaplatin. We also analyzed the correlation between the dose and the AUC (unit: lg h/ml) of CDGP administered through intra-arterial infusion.
Materials and Methods

Patients
The eligibility criteria for oral cancer patients who were treated at the Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa University Hospital were as follows; (1) no prior treatment of cancer, (2) age [20 years, (3) performance status (WHO) 0-2, (4) hematological white blood cells (WBC)[3,000/ll, platelet count [100,000/ll.
All patients received the routine medical care specified for cancer treatment, including blood chemistry, cell counts, standard laboratory tests, Chest film, CT, MRI, PET, and Scintigraphy. Creatinine clearance, based on 24-h urine collection, was carefully measured at least twice for each patient before chemotherapy. The value of CCr was adjusted using the following formula Table 1 shows the patient characteristics. Thirty-seven Japanese adult patients (68 courses of chemotherapy) were eligible for this study.
Typical regimens (Table 2 ) of this chemotherapy consisted of 5 days of 24-h continuous intravenous infusion of 5-Fu (750-1,000 mg/day/body) and a single shot of CDGP on day 4. CDGP was administered via a transfemoral approach using the Seldinger technique (Fig. 1) . The routine diagnostic angiographic procedure was accomplished with a standard diagnostic catheter using digital subtraction angiography (DSA), while the vascularity and the extent of the tumor were evaluated with dynamic CT. Typically, blood samples were taken at 8-12 time points after administration of CDGP, as follows: -1, 0, 0.5, 1, 2, 3, 5, 7, 12, 24, 48, 72 h, respectively (Fig. 2) . The 0 h refers to the point immediately after completion of the injection. In some cases, after 24 h, further sampling of the blood was not carried out because the platinum concentrations in the plasma were below the lowest detectable level. Total and free platinum concentrations in the plasma were measured, and the AUC (lg h/ml) was also calculated based on the platinum concentrations. The total sample number was 684, with 10.1 samples as an average taken from one course of chemotherapy for each patient. The superselective intra-arterial infusion chemotherapy was applied for the purpose of neo-adjuvant and/or induction therapy. Most of the patients who received surgery and/or radiation therapy completely recovered from the hematological nadir caused by the chemotherapy. It is important to point out that among this group there was no concomitant therapy, e.g., irradiation, during the course of chemotherapy. It also should be noted that this study was approved by the ethics committee of our institution and that the written and informed consent of the patients was obtained. 
Measurement and Data Analysis
The concentrations of total and free (non-protein bound) platinum in the blood plasma were measured with an atomic absorption spectrometry assay [15] at Shionogi Biochemical Laboratories (Osaka, Japan). The AUC of free platinum was calculated by the trapezoidal method from zero time to the last sampling time [16] . The pharmacokinetics analysis package WinNonlin Ò Version 2.1 (Pharsight Corporation, California, USA) was used to analyze the AUC.
Platinum clearance (CL) was obtained using the following formula:
Age Parameter Value as a target AUC CDGP was given according to the age of the patient (Table 3) . However, the APV number was modified slightly for each patient according to their condition, e.g., physical status, hematological status, and previous medical history. This formula was correlated with our dose setting for CDGP, and the administered dose was calculated by the following equation. The AUC of CDGP was estimated as being four times the AUC of CBDCA based on several studies [17] [18] [19] Table 4 summarizes the measurements obtained, including the AUC. A total of 684 samples were obtained during 68 courses of chemotherapy in 37 patients. The average administered dose of CDGP was 133.5 ± 33.1 mg (mean ± SD). The AUC ratio, based on the total platinum AUC compared to the AUC from free platinum, was 73.7 %. Within 24 h, all platinum in the plasma had been eliminated in all of the patients. Table 5 shows the data of hematological toxicity related to this chemotherapy. As can be seen, both WBC and platelets decreased significantly after the chemotherapy, and hemoglobin also decreased, though not significantly. This chemotherapy had no adverse effects on renal function (Table 6 ).
In this study, the patient age showed a significant negative correlation with creatinine clearance (CCr) (r = 0.522, p value for slope\0.001) and clearance of free platinum (CL) from CDGP (r = 0.409, p value for slope \0.001) (Fig. 3A, B) . BSA (m 2 ) did not show a significant co-relationship (r = 0.219, p value for slope [0.001) with CL or with CCr (r = 0.046, p value for slope = 0.011) (Fig. 3C) . The administered dose was calculated based on CCr and the patient's age. The final measured AUC based on free platinum showed a significant relationship with Fig. 4 . Figure 5 shows the relationship between CL and CCr and dose. CL showed a significant correlation with both CCr (r = 0.447, p value for slope \0.001) and dose (r = 0.467, p value for slope \0.001). The AUC based on free platinum showed a correlation with CCr (Fig. 5c) .
Discussion
When an anti-tumor drug is given by venous administration, it is diluted during circulation. In addition, some parts of the drug are metabolized or eliminated before reaching the tumor. In contrast, when the drug is given by intraarterial infusion, the drug bypasses the hepatic metabolism and directly enters the tumor tissue. Higher drug concentrations may therefore be obtained because the drug is directly injected into the arteries feeding the tumor. It is well known that anti-tumor efficacy is closely related to drug concentrations in the tumor [20] . However, it is also a fact that tumor drug concentrations resulting from intraarterial infusion might easily be affected by a number of factors. These include the distribution of the feeding arteries that are chosen, the infusion time, blood inflow and outflow rates, and the size and location of the tumor. Therefore, it may be difficult to predict with accuracy the platinum concentrations in the tumor tissue when given via AUC total platinum (lg h/ml) ± SD 19.07 ± 5.39
AUC free platinum (lg h/ml) ± SD 14.23 ± 3.58
Cmax total platinum (lg/ml) ± SD 5.56 ± 1.59
Cmax free platinum (lg/ml) ± SD 4.91 ± 1.24 Table 6 Renal function Pre-chemotherapy CCr (ml/min) ± SD 92.35 ± 27.27 * Post-chemotherapy CCr (ml/min) ± SD 89.84 ± 27.83 * arterial infusion. Nonetheless, it can be predicted with relative certainty that platinum concentrations in the tumor tissue, when the platinum is administered by superselective intra-arterial infusion, are likely to be much higher than with the dosage given by conventional venous infusion. In fact, in some studies using CDDP and CBDCA it has been reported that platinum concentrations in the tumor with intra-arterial infusion are 2-7 times higher than in similar tumors given the same chemotherapeutic agent via intravenous infusion. This result is concomitant with a relatively higher response rate [19, 21] . In clinical settings, both CDDP and CBDCA have been used as drugs for arterial chemotherapy with favorable results reported [10-12, 14, 22] . However, there is little data regarding intraarterial infusion chemotherapy with CDGP. With regard to dose-clearance studies including AUC with CDGP, several reports on the clinical base have been published [9, 23, 24] . Ishibashi et al. [24] have reported a formula for predicting the optimal dosage of CDGP based on renal function for conventional intravenous chemotherapy. They found that only creatinine clearance is a significant covariate of the clearance of CDGP, a finding that is supported by our study. This formula was developed based on a large number of Japanese cancer patients who had cancer in different organs throughout the body and patient data that were obtained from multiple institutions in Japan. In contrast, there is little basis for comparison between these two formulas due to the fact that our formula was established using data from intra-arterial infusion chemotherapy. It has been reported that the platinum concentrations in plasma and the AUC of free platinum by intravenous infusion are significantly different from those with intra-arterial infusion, even when the same doses are given [19, 25] . CDGP has a short elimination half-life (1.1-4.4 h) and a pharmacokinetic profile very similar to that of CBDCA [18, 26] . The limiting factor of CDGP is thought to be hematological toxicity, which has also been found with CBDCA. We tried to modify the formula that Calvert et al. [27] developed for CBDCA in order to determine the optimal dose for CDGP. The anti-tumor activity and pharmacokinetics of CDGP in comparison with CDDP and CBDCA have been previously reported [18] . In these articles [17] [18] [19] , the anti-tumor activity and the AUC for free platinum of CDGP were report to be 3.6-4 times higher than those of CBDCA when compared with the same dose. Therefore, we used the following formula to The target AUC was determined based on the patient's age due to its linear relationship with the physiological status and tolerance for anti-tumor agents. In fact, in our study the patient's age showed a significant correlation with both creatinine clearance and clearance of CDGP. For conventional intravenous chemotherapy, the range from 80 to 100 mg/m 2 of CDGP is recommended according to the results of clinical trials [5, 28, 29] . The dose administered is determined based on the body surface area (BSA: m 2 ). If a dose based on BSA is applied, the administered dose ranges from 121.6 mg (80 mg/m 2 ) up to 152.0 mg (100 mg/m 2 ) per body. The average dose calculated based on the 24-h CCr in this study was 133.5 mg per body, which is almost at the center of the range of the BSA-based dose setting. However, for each individual, the actual dose administered was not totally correlated to the BSA base dose. According to the results of our study, BSA seems to be a relatively poor index when used for determining dose because BSA does not show a statistically significant correlation with the clearance of CDGP (r = 0.046, p value = 0.01149 [ 0.01). In addition, BSA did not show any significant correlation with creatinine clearance. Finally, it would presumably be difficult to predict the side effects (e.g., hematological toxicity and gastrointestinal disturbance) individually after administration with a dosage based solely on BSA. For CBDCA, the relationship between the AUC, anti-tumor activity, and side effects has been investigated thoroughly [30] [31] [32] . The AUC of CDGP should also be a useful index for the purpose of predicting not only anti-tumor activity, but also other adverse side effects. It has been reported that the AUC of CDGP has a significant co-relationship to thrombocytopenia [23, 33] . Therefore, it is reasonable to conclude that the AUC should be optimized and individualized for patients being administered chemotherapy, even in cases where intraarterial infusion is used. If one can estimate the AUC of CDGP, it may then be possible to predict both the efficacy of the course of chemotherapy and the adverse side effects with a relatively high level of accuracy. However, we will need to evaluate the details of the relationship of the individualized AUC CDGP and the efficacy in relation to adverse effects in a future study.
In our results, a certain level of myelosuppression, e.g., leukocytopenia or thrombocytopenia, was observed. Its occurrence seemed to be within a modest and acceptable range compared to conventional chemotherapy with nedaplatin [5, 6, 8, 28, 29, 34] . In addition, we found no statistical significant adverse effect with regard to the concentrations of hemoglobin and renal function in preversus post-chemotherapy. In particular, with regard to preserving renal function, it should be noted that our superselective intra-arterial chemotherapy with a CDGP dose setting based on renal function most likely can minimize renal toxicity.
In conclusion, the dose-clearance formula that was established by our study can most likely be utilized to accurately predict the optimal administered dose of CDGP. This formula is based on the creatinine clearance of the cancer patient, allowing the clearance of CDGP to be estimated and individualized in terms of the dose. Although further clinical studies may be necessary in order to fully investigate the relationship between the AUC of CDGP and the side effects using superselective intra-arterial infusion chemotherapy, our current findings remain quite promising. However, we also should note that it will be most critical to investigate how to influence the 5-10 year survival rates of patients finally with our superselective intra-arterial infusion chemotherapy with CDGP.
